TGFβ Receptor II/TGFBR2 antibody | knockout validation

TGFβ Receptor II/TGFBR2 antibody | knockout validation | Santa Cruz sc-17799

This is a knockout-validated antibody summary, based on the publication "Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

[enlarge]

TGFβ Receptor II/TGFBR2 antibody | knockout validation | Santa Cruz sc-17799 figure 1

Figure 1. CRISPR/Cas9-mediated knockout of TGFBR2 in NP460 (NP460KO) cells resulted in the loss of TGFBR2. No pSmad2 and pSmad3 expression were detected in NP460KO cells following TGF-β1 treatment. Re-expression of wild-type TGFBR2 in NP460KO cells restored its response to TGF-β1 as shown by the induction of pSmad2 and pSmad3. NP460KO cells showed significant growth inhibition when compared with parental NP460 cells after TGF-β1 treatment. From [1].

Antibody information

Mouse monoclonal IgG2b κ

Company: Santa Cruz

Antibody: TGFβ Receptor II/TGFBR2

Catalog number: sc-17799

Summary: Mouse monoclonal antibody against amino acids 1-567 representing full length human TFGβ RII. Recommended for detection of TGFβ RII of mouse, rat and human origin by western blot, immunoprecipitation, immunofluorescence, immunohistochemistry (paraffin), and ELISA.

Validation Method

Western blot

Sample

WT and TGFBR2 KO NP460 cells.

Primary incubation

1:1,000 dilution.

References

Bruce J, To K, Lui V, Chung G, Chan Y, Tsang C, et al. Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape. Nat Commun. 2021;12:4193 pubmed publisher

contribute

If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.